I didn’t mean to upset you. I think you’re one of the most brilliant scientists I’ve come across.
Let’s go though this in order then:
1. What did you mean by your first comment? I’ve interpreted it wrong apparently. Sorry. 2. What is inconvenient about 2nd day scans? Like what is actually inconvenient about having a better opportunity to be diagnosed with cancer? 3. When, roughly, will the FDA approve the use of a new scanner and agent for any sort of indication? Roughly. Like are there trials happening right now where we can guesstimate when they’ll be able to be used? How far advanced are the trials? What sort of data are we getting from the trials?
I’ve never said anything about Cu64 and market share. I’ve got no clue what sort of market share they’ll get. I have my theories sure. You seem to be very concerned about it though.
CU6 Price at posting:
$6.41 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)